Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 OCT 19 ... is directly related to diabetic microvascular complications and may also contribute to macrovascular complications. In this way, hyperglycemia appears to perpetuate a vicious cycle of ... orthostatic hypotension. About Type 2 Diabetes Diabetes (diabetes mellitus) is a chronic disease in which the body does not produce or properly use insulin (a hormone that is needed for ...
2009 NOV 16 ... There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JANUMET or any other oral anti-diabetic drug. Dosing of ... such as JANUMET." JANUMET is contraindicated in patients with renal disease, renal dysfunction, or abnormal creatinine clearance; and acute or chronic metabolic ...
2009 NOV 9 ... of early microcirculatory alterations in prediabetes, diabetes, and diabetic micro- and macrovascular complications. Data from recent population-based studies suggest that retinal arteriolar ... narrowing, for example, is associated with risk of diabetes and coronary artery disease, whereas retinal venular widening is associated with development and progression of ...
2009 SEP 30 ... study was undertaken to investigate whether anti-beta(2)GPI and aCL are correlated with macrovascular disease, including ischemic digital loss and PAH, in SSc patients. Seventy-five SSc patients ...
2009 AUG 24 ... HbA(1c) goals may be appropriate in older patients with advanced microvascular and macrovascular disease, other comorbid conditions, and a history of severe hypoglycemia," wrote S. Mudaliar ...
2009 OCT 19 ... currency sign5 cm, a total tumor diameter a parts per thousand currency sign9 cm without macrovascular invasion, lymph node invasion and extrahepatic metastasis (referred to as the ... (referred to as the ''Shanghai criteria''), resulted in overall survival (OS) and disease-free survival (DFS) rates that were similar to the Milan criteria. Multivariate analysis ...
2009 AUG 24 ... across each stage of albuminuria was equivalent to the risk conferred by preexisting macrovascular disease. In addition, the glomerular filtration rate was independently associated with ...
2009 OCT 19 ... in diabetic patients are rare, and reports on associations of serum adiponectin with macrovascular disease have been inconsistent. In contrast to existing data on serum adiponectin, this study ...
2009 OCT 26 ... more likely to have nephropathy (OR 2.17, 95% CI 1.29-3.68, per SD decrease in CRAE) and macrovascular disease (OR 3.17, 95% CI 1.59-6.34, per SD decrease in CRAE), but not neuropathy (OR 1.10, 95% ...
2009 NOV 23 ... of microvascular events. There is, however, continuing uncertainty about its impact on macrovascular disease." "The aim of these analyses was to generate more precise estimates of ...
2009 AUG 31 ... and endothelial markers in people with Type 1 diabetes with low likelihood of macrovascular disease," researchers in the United Kingdom report. "Sixty-one young people with ...
2009 AUG 24 ... among the four cities (P < 0.001). who simultaneously suffered microvascular and macrovascular diseases had higher direct medical cost (7600) than those with macrovascular (6000) (P = ... medical cost (7600) than those with macrovascular (6000) (P = 0.012) and microvascular disease (5364) (P < 0.001), and those without both (3600) (P < 0.001). The correlation was ...
2009 NOV 5 ... with cerebrovascular damage suggests vascular hypertrophy in the microvascular and macrovascular bed," wrote D. Baleanu and colleagues, University Hospital. The ... vessels and WLR of retinal arterioles may point to different stages of cerebrovascular disease and/or different pathophysiological changes in the arteriolar wall. (Invest Ophthalmol ...
2009 AUG 31 ... circulating markers of endothelial dysfunction in people with type 1 diabetes without macrovascular disease or microalbuminuria. Diabetologia, 2009;52(8):1464-1473). For additional ...
2009 AUG 31 ... was significantly reduced (mean difference -0.15 [95% Cl -0.28 to -0.031). A history of macrovascular disease and current smoking were significant determinants of slower information-processing speed ...
2009 SEP 28 ... coronary disease, 24%; stroke, 15%; amputation, 9%; nephropathy, 3%; retinopathy, 2%. Macrovascular complications made up 86% of the annual direct costs and 95% of the annual indirect ...
2009 AUG 31 ... largely due to cardiovascular disease." "Genetic variants implicated in macrovascular disease are therefore excellent candidates to assess for association with diabetic nephropathy. ...
2009 NOV 23 ... from Rotherham, the United Kingdom, "Hyperglycemia is associated with microvascular and macrovascular complications. Intensive glucose control has been shown to reduce microvascular ... to reduce microvascular complications." "Nevertheless, cardiovascular disease remains the leading cause of death in patients with type 2 diabetes. A positive ...
2009 AUG 18 ... be required to reduce the risk of hypoglycemia when used in combination with ONGLYZA. Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of ... Bristol-Myers Squibb to further the understanding of how best to treat this challenging disease and help adult patients achieve their treatment goals." ONGLYZA™ (saxagliptin) ...
Subject: Bristol-Myers Squibb Company and AstraZeneca
2009 AUG 17 ... be required to reduce the risk of hypoglycemia when used in combination with ONGLYZA. Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of ... Bristol-Myers Squibb to further the understanding of how best to treat this challenging disease and help adult patients achieve their treatment goals." ONGLYZA™ (saxagliptin) ...
Subject: Bristol-Myers Squibb Company and AstraZeneca
